AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01313507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NewGam
Description: The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
Study NCT01644643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime - Avibactam ( CAZ-AVI)
Description: Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
Study NCT01644643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
Study NCT01644643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
Study NCT01060943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KOKEN
Description: atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
Study NCT01060943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atelocollagen Filler
Description: 1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
Study NCT02076945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)
Study NCT02076945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)
Study NCT01159093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Decision Support
Description: Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
Study NCT01159093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Decision Support
Description: Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
Study NCT01159093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Decision Support and Clinician Decision Support
Description: This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
Study NCT01159093 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual care
Study NCT04236271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: connected objects
Description: a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
Study NCT05725122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Description: Extracorporeal shock wave lithotripsy will given to the patients
Study NCT02318407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 403
Description: AMG 403 for the treatment of subjects with osteoarthritis
Study NCT02318407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study NCT04185311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03341923 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A multifocal contact lenses
Description: Hydrogel multifocal contact lenses for daily disposable wear
Study NCT02930369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM peeling surgery
Description: 4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
Study NCT02930369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling surgery
Description: 4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
Study NCT05046678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Control
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
Study NCT01290185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of different catheters for continuous nerve block
Description: Placement different catheters adjacent to the femoral
Study NCT05725122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.
Description: Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
Study NCT01290185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of different catheters for continuous nerve block
Description: Placement different catheters adjacent to the femoral
Study NCT01765231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir prophylaxis
Description: Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
Study NCT01765231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Observation arm
Description: Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
Study NCT02191098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
Study NCT05046678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontally healthy
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study NCT02768467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Matrix Graft Placement
Description: Subject will receive a covering for the wound post buccal mucosa removal.
Study NCT02768467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Stitches
Description: Subject will not receive stitches post buccal mucosa removal.
Study NCT04065334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose training
Description: 4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
Study NCT04065334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low dose training
Description: 1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous sufentanil
Description: The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous sufentanil
Description: The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous hydromorphone
Description: The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous hydromorphone
Description: The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous sufentanil and dexmedetomidine
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous sufentanil and dexmedetomidine
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous hydromorphone and dexmedetomidine
Description: The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
Study NCT04111328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous hydromorphone and dexmedetomidine
Description: The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
Study NCT01736215 — intervention group
Intervention type: DRUG
Intervention: Erythropoietin: Observational study
Description: This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
Study NCT05058534 — intervention group
Intervention type: DEVICE
Intervention: Multiline Neo®
Description: Multiperfusion neonatal system
Study NCT04595916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine injection 930 mg QD
Description: Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
Study NCT01173679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dasatinib
Description: Taken orally once a day on days 1-14 of each 28-day cycle
Study NCT01173679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
Study NCT01173679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine
Description: Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
Study NCT00710944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
Study NCT05046678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP > 30% in the full mouth and nonsmokers if they had no previous history of smoking
Study NCT00846846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor® Zotarolimus Eluting Coronary Stent System
Description: Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
Study NCT03457077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: A brief motivational intervention with feedback about drinking levels compared to norms
Study NCT03457077 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief intervention
Description: A brief motivational intervention with feedback about drinking levels compared to norms
Study NCT05046678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP > 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study NCT04595916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Isoglycyrrhizinate injection 200 mg QD
Description: Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
Study NCT03340753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KBP-5074 Capsule
Description: KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
Study NCT03340753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074 Tablet
Description: KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
Study NCT00960830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 15 mg daily tablets
Study NCT00960830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: 15 mg daily
Study NCT02374307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and education
Description: Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
Study NCT01125020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and oxaliplatin
Description: Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
Study NCT01125020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin, 5-Fu and cisplatin
Description: Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
Study NCT01293760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate insertion
Description: Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
Study NCT01293760 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 weeks interval insertion
Description: Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
Study NCT03325400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste non-fluoride and fluoride
Description: Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
Study NCT03325400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Toothpaste non-fluoride and fluoride
Description: Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
Study NCT05046678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with periodontitis
Description: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking
Study NCT05046678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontitis
Description: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study NCT03010813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic single port surgery and NOTES
Description: Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
Study NCT02290613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake.
Study NCT02290613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets)
Study NCT02346526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Tests
Description: Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
Study NCT02346526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Standard CT scans will be carried out prior to treatment, week 9, and week 25.
Study NCT04346693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy recommended by the Ministry of Health of the Russian Federation.
Description: Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days
Study NCT04346693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection
Description: Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days
Study NCT04346693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation
Description: Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.